Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case–control design

Figures & data

short-legendFigure 1

Table 1 Details of vaccination status among children who received at least one dose of LLR

Age at vaccination (month)	Number of children (%)
	First dose	Second dose	Third dose
0–	17 (1.3)	0	0
6–	642 (47.2)	0	0
12–	342 (25.2)	6 (3.4)	0
18–	256 (18.1)	83 (46.6)	0
24–	104 (7.7)	54 (30.3)	1 (8.3)
30–	38 (2.8)	23 (12.9)	8 (66.7)
36–	13 (1.0)	12 (6.8)	3 (25.0)
Total	1412	178	12

Table 2 Estimates of the odds ratio (OR) for vaccination with human rotavirus vaccine (HRV) in the effectiveness and bias indicator studies

	Proportion vaccinated (%)
	Case patients	Control subjects	OR (95% CI)	P value
Effectiveness study: non-conservative scenario
All severities
Against all serotypes	51/305 (16.7%)	304/1220 (24.9%)	0.65 (0.48–0.87)	0.0062
Against G3	31/204 (15.2%)	324/1321 (24.5%)	0.59 (0.40–0.87)	0.0076
Moderate/severe illness
Against all serotypes	23/147 (15.7%)	332/1378 (24.1%)	0.61 (0.39–0.95)	0.0305
Against G3	12/100 (12.0%)	343/1425 (24.1%)	0.47 (0.25–0.85)	0.0136
Effectiveness study: conservative scenario
All severities
Against all serotypes	53/305 (17.4%)	305/1220 (25.0%)	0.68 (0.50–0.92)	0.0111
Against G3	33/204 (16.2%)	325/1321 (24.6%)	0.63 (0.43–0.92)	0.0162
Moderate/severe illness
Against all serotypes	24/147 (16.3%)	334/1378 (24.2%)	0.64 (0.41–0.99)	0.0448
Against G3	13/100 (13.0%)	345/1425 (24.2%)	0.50 (0.28–0.91)	0.0224
Bias indicator study: non-conservative scenario
All severities	49/226 (21.7%)	224/904 (24.8%)	0.86 (0.63–1.19)	0.3749
Bias indicator study: conservative scenario
All severities	50/226 (22.1%)	226/904 (25.0%)	0.88 (0.64–1.20)	0.4122

Non-conservative scenario: vaccination history of those children who could not provide vaccination card was defined as having not received LLR; Conservative scenario: vaccination history of those children who could not provide vaccination card was defined as having received LLR.

Table 3 Sensitive analysis of VE against all serotypes of RV with different age matching based on the conservative scenario

	Proportion vaccinated (%)
	Case patients	Control subjects	OR (95% CI)
Matching age <90 days between cases and controls
All severities	53/305 (17.4%)	305/1220 (25.0%)	0.68 (0.50–0.92)
Moderate/severe illness	24/147 (16.3%)	334/1378 (24.2%)	0.64 (0.41–0.99)
Matching age <60 days between cases and controls
All severities	53/305 (3.49%)	299/1214 (19.68%)	0.70 (0.52, 0.94)
Moderate/severe illness	17/109 (1.12%)	335/1410 (22.05%)	0.61 (0.36–1.03)
Matching age <45 days between cases and controls
All severities	53/305 (3.50%)	294/1209 (19.42%)	0.71 (0.52–0.96)
Moderate/severe illness	17/109 (1.12%)	330/1405 (21.80%)	0.62 (0.37–1.04)